Although the recently placed Canadian vaccine order is unlikely to lead to dramatic top line growth for Bavarian Nordic, the order is a significant strategic step toward the end goal, the company’s CFO says.
Lundbeck’s blockbuster candidate, antidepressant Brintellix, is likely to be given general conditional reimbursement. The recommendation from the Danish Reimbursement Committee is in line with Lundbeck’s own expectations, says the director of Lundbeck Pharma Denmark.
Ambu has work to do in Q4 of its fiscal year 2013/2014 if it is to live up to its full year guidance. CEO Lars Marcher says it is all about the trend, which has looked quite solid in the last two quarters.
Financial news were few and far between from Zealand Pharma in the latest quarter, but the clinical programs are developing according to plan, says CEO David Solomon, who also comments on the recent sale of Santaris.
Lars Kongsbak, CEO in Exiqon, is deeply disappointed with last week’s lowering of the company's full year guidance, which is caused by a unexpected turn of events. But he is hopeful about the long term business prospects.
The Danish hearing devices group GN ReSound is conquering market shares for the 16th quarter running, with the newly-launched iPhone-compatible devices accounting for most of the growth. But how long can the company keep its momentum with rivals breathing down its neck?
Novo Nordisk has decided to accept the fine the company was given by the Danish State Attorney in a case raised by the Danish FSA in connection with US approval agency FDA’s rejection of diabetes drug Tresiba.
Plans for a US IPO were what eventually led to the sale of Santaris to a Big Pharma outfit that Martin Bonde calls “the biggest gorilla in the jungle” – and it is a sale that could have a huge significance for other Danish biotechs.
NeuroSearch has been fined DKK 5 million in a case that sees the Danish biotech company, which is under liquidation, convicted of market manipulation. Former CEO and current ALK CFO, Flemming Pedersen, has also been met with a massive fine.
One thing is of special importance if Danish biotech wants to shed its label as a “loser business”, says a long-time investor in the biopharma industry. But the dream of a glorified sector is still alive.
Novo Nordisk has not managed to reconquer an important contract with a US pharmacy benefits manager. According to an industry analyst, it suggests that the Danish group is unwilling to lower prices in order to get its foot back in the door.
The large-scale IPO of biotech company Serendex has not been off to a flying start. The share price has plummeted since the IPO on July 11th, which has compelled the CEO to comment on the adverse development.
An employee’s level of commitment can be affected by circumstances in the family, such as disease – and the company should be sensitive to that. But if people are down-right uncommitted, the corporate culture is so strong that it will gradually expel them. Lars Rebien, at the peak of his career, spoke to Medwatch about the unique Novo spirit, about failing politicians, and about growing softer.
Gitte Pedersen’s career began in Novo Nordisk and the Danish drug giant led her to the US, where she is now CEO and co-founder of a diagnostics company in Manhattan – a career that is partly formed by a past peopled by engineers and women’s rights activists.